Latest news with #EXEL
Yahoo
07-07-2025
- Business
- Yahoo
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth. Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. EXEL is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 32% year-over-year for the current fiscal year, with sales growth of 7.9%. 10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.33 to $2.64 per share. EXEL boasts an average earnings surprise of 48.6%. Looking at cash flow, Exelixis is expected to report cash flow growth of 135.6% this year; EXEL has generated cash flow growth of 10.8% over the past three to five years. EXEL should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-07-2025
- Business
- Yahoo
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. EXEL is a Zacks Rank #2 (Buy) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 17.5X for the current fiscal year compared to the Medical - Biomedical and Genetics industry's P/E 19.4X. Additionally, EXEL has a PEG Ratio of 0.8 and a Price/Cash Flow ratio of 24X. Value investors should also note EXEL's Price/Sales ratio of 5.5X. Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. 10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.33 to $2.64. EXEL has an average earnings surprise of 48.6%. EXEL should be on investors' short list because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-07-2025
- Business
- Yahoo
2 Stocks to Buy With Less Than $50
Pfizer is slowly building a foundation that will help its business recover from recent headwinds. Encouraging developments on the clinical front should boost shares of cancer specialist Exelixis. 10 stocks we like better than Pfizer › One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices. Here are two excellent examples in the healthcare industry: Pfizer (NYSE: PFE) and Exelixis (NASDAQ: EXEL). These drugmakers are worth investing in, and both are changing hands for under $50 apiece. Here is what investors need to know. Pfizer's shares have declined significantly over the past few years as its revenue and earnings dipped following its coronavirus-related success. What's more, the company could face more trouble soon. The drugmaker will encounter significant patent cliffs in the next few years, particularly for Eliquis, an anticoagulant. However, at about $25 per share, Pfizer looks attractive. Here are four reasons why. First, the company should succeed in rejuvenating its lineup. Pfizer has improved its pipeline over the past few years. It has also earned major approvals. Though they are not yet helping the company's revenue move in the right direction consistently, that will happen in time. Second, Pfizer has been engaged in cost-cutting efforts to help boost its bottom line. Pfizer is still at it and is planning to reduce expenses even more through 2027. Third, Pfizer offers a terrific dividend program. The company has increased its payouts by 19.45% in the past five years. Pfizer's forward yield is 7.1% -- that's well above the S&P 500's average of 1.3%. Pfizer should continue to reward loyal shareholders in this manner. Lastly, the stock appears to be more than reasonably valued. Pfizer's forward price-to-earnings ratio comes in at a dirt-cheap 8.3, well below the average of 16.1 for the healthcare industry. Pfizer's stock might not recover overnight. However, for patient, income-seeking investors, it is worth investing in the company right now. Over time, that investment could pay for itself. Exelixis is a relatively small drugmaker that specializes in oncology. The company's top-selling product is Cabometyx, which is approved to treat several kinds of cancers, most notably some forms of liver and kidney cancer. Cabometyx has been a hit and has helped Exelixis' revenue and earnings move in the right direction for years. However, the biotech company has become even more attractive over the past 18 months. Here are three things that happened. First, Exelixis won a patent litigation case that will help keep a Cabometyx generic off the market until early 2030. Had the drugmaker lost this lawsuit, it might have been disastrous for its financial results. Second, Cabometyx won another label expansion, this time for the treatment of pancreatic neuroendocrine tumors. Cabometyx has maintained an upward sales trajectory by holding a leading market share for medicines of its type among patients with renal cell carcinoma (kidney cancer), and thanks to label expansions. If it's not broken, don't fix it. Third, Exelixis recently announced positive top-line results for its next-gen cancer medicine, zanzalintinib, in a phase 3 study that enrolled patients with metastatic colorectal cancer. Although colorectal cancer is highly treatable when caught early, as Exelixis points out, five-year survival rates drop once it has metastasized, meaning there is an unmet need in that niche. The biotech's zanzalintinib could help fill that need and help decrease the company's exposure to Cabometyx, all in one fell swoop. With all that going on, the future looks brighter than ever for Exelixis. Shares are changing hands for $44 apiece. Investing in the stock and holding on to it for five years or more could lead to solid returns. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Exelixis. The Motley Fool has positions in and recommends Exelixis and Pfizer. The Motley Fool has a disclosure policy. 2 Stocks to Buy With Less Than $50 was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
30-06-2025
- Business
- Yahoo
Zacks.com featured highlights include Exelixis, Lyft and Kinross Gold
Chicago, IL – June 30, 2025 – Stocks in this week's article are Exelixis, Inc. EXEL, Lyft, Inc. LYFT and Kinross Gold Corp. KGC. Stock markets have been experiencing significant volatility of late. This is largely because of geopolitical tensions and the ongoing trade war. These near-term risks have led to expectations of economic slowdown and rising inflation. In such an uncertain environment, retail investors face significant challenges in selecting the right stocks and achieving strong returns. One way to cut short this task is to follow brokers' recommendations. In this regard, stocks like Exelixis, Inc., Lyft, Inc. and Kinross Gold Corp. are worth considering. As brokers directly communicate with top management, they have more insight into what is happening in a particular company. They assess a company's publicly available documents and even attend conference calls. Brokers have more understanding of the overall sector and industry. They place company fundamentals against the current economic backdrop to determine how a particular stock will fare as an investment. When brokers upgrade a stock, one can easily rely on their judgment. Yet, depending on broker upgrades is not enough to build your investment portfolio. A few other factors should be taken into account to ensure steady returns. Alameda, CA-based Exelixis is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. Currently, EXEL has four approved drugs in its portfolio. Exelixis' 2025 earnings are expected to rise 32% year over year. EXEL, which currently carries a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks. Lyft, based in San Francisco, CA, was founded in 2012. LYFT operates multimodal transportation networks in the United States and Canada. LYFT's 2025 earnings are projected to grow 15.8% on a year-over-year basis. Lyft, carrying a Zacks Rank #2 at present, has witnessed a 2.5% upward revision in broker ratings over the past four weeks. Based in Toronto, Canada, Kinross is involved in the exploration and operation of gold mines. KGC ranks among the top 10 gold mining companies globally. Kinross' 2025 earnings are expected to jump 69.1% year over year. KGC, presently carrying a Zacks Rank #2, has witnessed an 8.3% upward revision in broker ratings over the past four weeks. Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial of the Research Wizard today. For the rest of this Screen of the Week article please visit at: Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. About Screen of the Week created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Strong Stocks that Should Be in the News Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>. Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kinross Gold Corporation (KGC) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Lyft, Inc. (LYFT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Exelixis (EXEL), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Exelixis currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Let's discuss some of the components of the Momentum Style Score for EXEL that show why this drug developer shows promise as a solid momentum pick. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area. For EXEL, shares are up 1.53% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 0.25% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 16.08% compares favorably with the industry's 3.88% performance as well. While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Exelixis have risen 15.14%, and are up 91.03% in the last year. In comparison, the S&P 500 has only moved 1.99% and 12.34%, respectively. Investors should also pay attention to EXEL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. EXEL is currently averaging 3,763,384 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with EXEL. Over the past two months, 10 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost EXEL's consensus estimate, increasing from $2.31 to $2.61 in the past 60 days. Looking at the next fiscal year, 9 estimates have moved upwards while there have been 1 downward revision in the same time period. Given these factors, it shouldn't be surprising that EXEL is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Exelixis on your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
